药物类型 T细胞疗法 |
别名 allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)、Herpes simplex virus thymidine kinase (HSV-Tk) donor lymphocytes、HSV-Tk + [5] |
靶点- |
作用机制 细胞替代物、免疫刺激剂 |
在研适应症- |
在研机构- |
非在研机构 |
最高研发阶段撤市 |
最高研发阶段(中国)- |
特殊审评- |
开始日期2009-10-27 |
申办/合作机构 |
开始日期2009-10-01 |
申办/合作机构 |
开始日期2008-10-01 |
申办/合作机构 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
血液肿瘤 | 欧盟 | 2016-08-18 | |
血液肿瘤 | 冰岛 | 2016-08-18 | |
血液肿瘤 | 列支敦士登 | 2016-08-18 | |
血液肿瘤 | 挪威 | 2016-08-18 | |
造血干细胞移植 | 欧盟 | 2016-08-18 | |
造血干细胞移植 | 冰岛 | 2016-08-18 | |
造血干细胞移植 | 列支敦士登 | 2016-08-18 | |
造血干细胞移植 | 挪威 | 2016-08-18 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床2期 | - | TK-DLI | 簾獵鬱廠觸簾糧窪淵淵(齋顧獵遞蓋憲窪簾夢簾) = 願鏇選獵遞夢鏇憲鹹鑰 築鹽願膚餘憲艱製衊廠 (鬱鹽廠鬱壓網糧遞蓋膚 ) 更多 | - | 2006-06-20 | ||
N/A | 8 | Tk-DLI | 衊簾顧簾壓憲糧鏇夢衊(壓顧糧願築艱範襯蓋憲) = Multiple doses of ganciclovir (10 mg/kg/die), in the absence of immunosuppressive drugs, quickly resulted in the complete resolution of all signs of GvHD 憲蓋遞窪築糧積範壓襯 (築獵觸衊窪築醖願遞製 ) 更多 | - | 2004-07-15 | ||
N/A | 8 | 膚顧範鬱糧廠醖願壓膚(鏇餘膚築襯窪鹽遞積鹽) = 1/8 patients experienced grade II biopsy-proven acute GvHD, involving the skin and the liver. The administration of multiple doses of ganciclovir (10 mg/kg/die), in the absence of immunosuppressive drugs, quickly resulted in the complete resolution of all clinical and biochemical signs of GvHD. Two patients of this series received unmodified DLI and died of refractory GvHD and disease progression. 憲窪衊鹹簾繭淵鬱繭鹹 (糧淵鏇繭選廠鬱顧醖選 ) | 积极 | 2002-05-01 |